12,977 results match your criteria Nephritis Lupus


Clinico-histomorphologic Characteristics of Lupus Nephritis, Experience at a Center at Dhaka.

Saudi J Kidney Dis Transpl 2021 Nov-Dec;32(6):1754-1763

Commandant, Armed Forces Institute of Pathology, Dhaka, Bangladesh.

Lupus nephritis (LN) is one of the most serious systemic lupus erythematosus complications since it is the major predictor of poor prognosis. We present the clinico-histomorphologic characteristics of LN at a center in Dhaka. The study group comprised diagnosed cases of LN on core-needle renal biopsy specimens received in the Department of Histopathology, Armed Forces Institute of Pathology, Dhaka, from January 2018 to June 2019. Read More

View Article and Full-Text PDF

Epidemiology of Pediatric Renal Diseases and its Histopathological Spectrum - A Single-Center Experience from India.

Saudi J Kidney Dis Transpl 2021 Nov-Dec;32(6):1744-1753

Department of Pathology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India.

Pediatric renal biopsy is an uncommon event, and the spectrum of the disease is evaluated and managed mostly on the clinical grounds. Compared to adults, the indications for renal biopsy in pediatric population are very few. We reviewed the pediatric renal biopsies received at our tertiary center in Mumbai, India, over a period of six years to study the incidence of various medical renal diseases, their spectrum on histology and its correlation with electron microscopy (EM). Read More

View Article and Full-Text PDF

Time for new therapeutic options in lupus nephritis.

Joint Bone Spine 2022 Aug 6:105451. Epub 2022 Aug 6.

Nephrology Department Hôpital Européen Georges Pompidou, Paris, France; Université de Paris, France. Electronic address:

View Article and Full-Text PDF

Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IV.

Ann Rheum Dis 2022 Aug 8. Epub 2022 Aug 8.

Pathology, Department of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy.

Objective: The International Society of Nephrology/Renal Pathology Society classification is the gold standard for the characterisation of lupus nephritis (LN) on renal biopsy, with therapeutic repercussions. Its recent revision simplified the current class subdivisions, eliminating the S/G forms of class IV, although data on a possible pathogenetic/clinical value of this subdivision are still contradictory.

Methods: 353 renal biopsies from Belimumab International Study in LN were assessed through central pathology review. Read More

View Article and Full-Text PDF

Comparison of circulating miR-148a and miR-126 with autoantibodies as biomarkers of lupus nephritis in patients with SLE.

J Immunoassay Immunochem 2022 Aug 8:1-14. Epub 2022 Aug 8.

Immunology Department, Iran University of Medical Sciences, Tehran, Iran.

Lupus nephritis (LN) is the main manifestation of systemic Lupus Erythematosus (SLE). MicroRNAs (miRNAs) and autoantibodies could be suitable candidate biomarkers of LN. This study evaluates the expression of circulating miR-148a and miR-126 along with anti-dsDNA, anti-C1q, and anti-C3b autoantibodies in SLE patients with LN (SLE + LN). Read More

View Article and Full-Text PDF

All Endocarditis Is Not Infective: Libman-Sacks Endocarditis.

Cureus 2022 Jul 3;14(7):e26526. Epub 2022 Jul 3.

Department of Child Health, College of Medicine and Health Sciences, Muscat, OMN.

Libman-Sacks endocarditis (LSE) is an uncommon disorder that might be confused with infective endocarditis. It is one of the systemic lupus erythematosus (SLE) manifestations that could present with heart failure. We report a 12-year-old girl who presented with a history of shortness of breath, joint pain for four weeks, and fever for about one week. Read More

View Article and Full-Text PDF

A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus.

J Autoimmun 2022 Aug 4;132:102869. Epub 2022 Aug 4.

Copenhagen Research Center of Autoimmune Connective Tissue Diseases (COPEACT), Copenhagen University Hospital, Rigshospitalet, Denmark.

Upregulation of interferon-regulated genes (IRGs), denoted IFN signature, in peripheral blood has been used as an indirect measure of IFN pathway activation in patients with systemic lupus erythematosus (SLE). However, it has not been determined, which IFN signatures that optimally reflect clinical disease activity. In this study, we determined an IFN signature based on the expression of 128 IRGs in whole blood from 34 SLE patients in a cross-sectional (CS) study, 11 with active lupus nephritis followed longitudinally (LS) and 15 healthy controls. Read More

View Article and Full-Text PDF

A Review of Lupus Nephritis.

J Appl Lab Med 2022 Aug 6. Epub 2022 Aug 6.

Division of Rheumatology, Schroeder Arthritis Institute, University Health Network, Toronto, Canada.

Background: Lupus nephritis (LN) is one of the most common severe organ manifestations of systemic lupus erythematosus (SLE). LN is associated with significant morbidity and mortality in SLE patients, as up to 20% of patients progress to end-stage renal disease (ESRD). The clinical manifestations of LN are variable, ranging from asymptomatic proteinuria to a myriad of manifestations associated with nephritic and nephrotic syndromes and ESRD. Read More

View Article and Full-Text PDF

Anti-C1q autoantibodies from systemic lupus erythematosus patients enhance CD40-CD154-mediated inflammation in peripheral blood mononuclear cells .

Clin Transl Immunology 2022 2;11(8):e1408. Epub 2022 Aug 2.

Laboratory of Clinical Immunology, Department of Biomedicine University of Basel Basel Switzerland.

Objectives: Systemic lupus erythematosus (SLE) is a clinically heterogeneous autoimmune disease with complex pathogenic mechanisms. Complement C1q has been shown to play a major role in SLE, and autoantibodies against C1q (anti-C1q) are strongly associated with SLE disease activity and severe lupus nephritis suggesting a pathogenic role for anti-C1q. Whereas C1q alone has anti-inflammatory effects on human monocytes and macrophages, C1q/anti-C1q complexes favor a pro-inflammatory phenotype. Read More

View Article and Full-Text PDF

Bullous systemic lupus erythematosus in females.

Int J Womens Dermatol 2022 Oct 25;8(3):e034. Epub 2022 Jul 25.

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Bullous systemic lupus erythematosus (BSLE) is a rare blistering presentation of systemic lupus erythematosus, typically affecting women with the highest incidence in those of African descent. The key pathogenic insult includes the formation of autoantibodies against type VII collagen, which weaken the basement membrane zone and lead to the formation of subepidermal blisters. The acute vesiculobullous eruptions in BSLE generally tend to affect photo-distributed areas, although they can arise unrelated to sun exposure (eg, mucous membranes, axillae). Read More

View Article and Full-Text PDF
October 2022

Could systemic immune inflammation index be a new parameter for diagnosis and disease activity assessment in systemic lupus erythematosus?

Int Urol Nephrol 2022 Aug 2. Epub 2022 Aug 2.

Department of Nephrology, University of Health Sciences, Bakirkoy Dr.Sadi Konuk, Education and Research Hospital, Zuhuratbaba, Tevfik Saglam Cad. No:11, Bakirkoy, 34147, Istanbul, Turkey.

Purpose: Systemic immune inflammation index (SII) has been used as a marker of inflammatory status in various diseases, but its role in systemic lupus erythematosus (SLE) is unknown. We aimed to investigate the role of SII in SLE and its association with disease activity and renal involvement.

Methods: In this retrospective study, 76 patients with SLE were compared with 76 age- and gender-matched healthy control group in terms of SII, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR). Read More

View Article and Full-Text PDF

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis.

Lupus Sci Med 2022 08;9(1)

Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Objective: Lupus nephritis is a key driver of morbidity and mortality in SLE. Detecting active nephritis on a background of pre-existing renal damage is difficult, leading to potential undertreatment and accumulating injury. An unmet need is a biomarker that distinguishes active lupus nephritis, particularly important in paediatrics where minimising invasive procedures is desirable. Read More

View Article and Full-Text PDF

Assessment of microvascular involvement in lupus nephritis patients by retinal OCT-angiography and kidney biopsies.

Clin Exp Rheumatol 2022 Jul 28. Epub 2022 Jul 28.

Ophthalmology Unit, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.

Objectives: Ocular and renal microvascular damage in lupus nephritis (LN) share similar physiopathological pathways that have investigated using traditional fundus examination and high-resolution colour electroretinography. Optical coherence tomography angiography (OCTA) is a recent, non-invasive technique for imaging the microvasculature of retina and choroid. Aim of the study was to investigate through OCTA analysis the relationship between retinal microvascular alterations and renal functional and histologic features. Read More

View Article and Full-Text PDF

Predisposing Factors of Tuberculosis Infection in Systemic Lupus Erythematosus Patients: A Single-Center Case-Control Study.

Cureus 2022 Jun 28;14(6):e26410. Epub 2022 Jun 28.

Internal Medicine, Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Jakarta, IDN.

Introduction: Indonesia has the second-highest tuberculosis cases in the world, according to the global WHO tuberculosis report, amounting to approximately 10% of the world's tuberculosis cases. Systemic lupus erythematosus (SLE) patients are at an increased risk for tuberculosis infection. This research aims to analyze the association between corticosteroid pulse dose, corticosteroid cumulative dose, SLE disease duration, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, and lupus nephritis status with the development of tuberculosis in SLE patients. Read More

View Article and Full-Text PDF

Construction of a Nomogram Discriminating Malignancy-Associated Membranous Nephropathy From Idiopathic Membranous Nephropathy: A Retrospective Study.

Front Oncol 2022 14;12:914092. Epub 2022 Jul 14.

Department of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Background: Based on the etiology, membranous nephropathy (MN) can be categorized into idiopathic membranous nephropathy (IMN) and secondary membranous nephropathy. Malignancy-associated membranous nephropathy (MMN) is a common type of secondary MN. Its incidence is only second to that of lupus nephritis. Read More

View Article and Full-Text PDF

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis.

Front Immunol 2022 14;13:935700. Epub 2022 Jul 14.

School of Medicine, Chang Gung University, Taoyuan City, Taiwan.

Introduction: Urine-soluble CD163 (usCD163) is released from alternatively activated macrophages involved in the resolution of inflammation in glomeruli and plays an important role in glomerulonephritis. This study explored the role of usCD163 in patients with systemic lupus erythematosus (SLE).

Materials And Methods: usCD163 concentrations were measured cross-sectionally in 261 SLE patients in Taiwan. Read More

View Article and Full-Text PDF

Systemic Lupus Erythematosus Patients With Related Organic Damage Are at High Risk of Hypothyroidism.

Front Endocrinol (Lausanne) 2022 15;13:920283. Epub 2022 Jul 15.

Department of Endocrinology, Shandong Provincial Hospital, Shandong University, Jinan, China.

Purpose: The aim of this study included determining the prevalence of hypothyroidism in patients with systemic lupus erythematosus (SLE), clarifying the clinical characteristics of SLE patients with hypothyroidism, and identifying the relationship between hypothyroidism and SLE-related organic damage. Another purpose was to analyze the relationship between SLE and thyroid autoantibody. We also intended to discuss the pathogenesis of hypothyroidism in SLE patients, which would provide clues for further investigation. Read More

View Article and Full-Text PDF

Health disparities in systemic lupus erythematosus-a narrative review.

Clin Rheumatol 2022 Jul 31. Epub 2022 Jul 31.

National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA.

Purpose Of Review: To describe root causes of health disparities by reviewing studies on incidence and outcomes of systemic lupus erythematosus (SLE) related to ethnic, race, gender, or socioeconomic differences and to propose solutions.

Recent Findings: SLE outcomes have steadily improved over the past 40 years but are not uniformly distributed across various racial and ethnic groups. Belonging to racial and ethnic minority has been cited as a risk factor for more severe disease and poor outcome in SLE. Read More

View Article and Full-Text PDF

Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.

Autoimmun Rev 2022 Jul 28;21(10):103158. Epub 2022 Jul 28.

Université de Lorraine, Inserm, DCAC and CHRU-Nancy, Vascular Medicine Division and Regional Competence Center for Rare Auto-Immune Diseases, Nancy, France. Electronic address:

Background: Microvascular renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their association with aPL is inconsistent among studies. Therefore, our objective was to investigate associations between microvascular renal lesions and aPL among systemic lupus erythematosus (SLE) patients.

Methods: Studies were selected if they included SLE patients with and without aPL positivity with a description of kidney biopsy identifying acute and/or chronic microvascular renal lesions as well as lupus nephritis. Read More

View Article and Full-Text PDF

Dissecting signalling pathways associated with intrarenal synthesis of complement components in lupus nephritis.

RMD Open 2022 Jul;8(2)

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany

Lupus nephritis is one of the most common and serious complications of systemic lupus erythematosus, attributed to increased morbidity and mortality. The in situ deposition of intrarenal immune complexes promote the accumulation of inflammatory cells and cause kidney injury in lupus nephritis. Among potential sources of intrarenal complement deposits, the concept of intrarenal complement synthesis has been described more than three decades ago in experimental lupus nephritis. Read More

View Article and Full-Text PDF

Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis.

Ann Rheum Dis 2022 Jul 29. Epub 2022 Jul 29.

Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece

Objectives: Patients with lupus nephritis (LN) are in urgent need for early diagnosis and therapeutic interventions targeting aberrant molecular pathways enriched in affected kidneys.

Methods: We used mRNA-sequencing in effector (spleen) and target (kidneys, brain) tissues from lupus and control mice at sequential time points, and in the blood from 367 individuals (261 systemic lupus erythematosus (SLE) patients and 106 healthy individuals). Comparative cross-tissue and cross-species analyses were performed. Read More

View Article and Full-Text PDF

Choosing the Right Treatment in Patients with Lupus Nephritis.

Clin J Am Soc Nephrol 2022 Jul 29. Epub 2022 Jul 29.

Department of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China

View Article and Full-Text PDF

Ambulatory Blood Pressure Patterns in Children, Adolescents, and Young Adults With Childhood-Onset Systemic Lupus Erythematosus and Normal Office Blood Pressure.

J Clin Rheumatol 2022 Jul 29. Epub 2022 Jul 29.

From the Division of Pediatric Nephrology, Department of Pediatrics.

Objective: Cardiovascular disease is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Hypertension (HTN) and nondipping are modifiable risk factors for cardiovascular disease. Limited studies are available for childhood-onset SLE (cSLE). Read More

View Article and Full-Text PDF

The lupus susceptibility allele DRB1*03:01 encodes a disease-driving epitope.

Commun Biol 2022 Jul 28;5(1):751. Epub 2022 Jul 28.

Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.

The HLA-DRB1*03:01 allele is a major genetic risk factor in systemic lupus erythematosus (SLE), but the mechanistic basis of the association is unclear. Here we show that in the presence of interferon gamma (IFN-γ), a short DRB1*03:01-encoded allelic epitope activates a characteristic lupus transcriptome in mouse and human macrophages. It also triggers a cascade of SLE-associated cellular aberrations, including endoplasmic reticulum stress, unfolded protein response, mitochondrial dysfunction, necroptotic cell death, and production of pro-inflammatory cytokines. Read More

View Article and Full-Text PDF

Short- and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria.

Clin J Am Soc Nephrol 2022 Aug 26;17(8):1150-1158. Epub 2022 Jul 26.

Division of Rheumatology, Hackensack University Medical Center, Hackensack, New Jersey

Background And Objectives: Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at a urine protein-creatinine ratio of ≥0.5 g/g. Read More

View Article and Full-Text PDF

AIM2-inflammasome role in systemic lupus erythematous and rheumatoid arthritis.

Autoimmunity 2022 Jul 26:1-12. Epub 2022 Jul 26.

Instituto Mexicano del Seguro Social, IMSS, Unidad de Investigación Biomédica, Delegación Zacatecas, Zacatecas, México.

The inflammasome AIM2 regulates multiple aspects of innate immune functions and serves as a critical mediator of inflammatory responses. AIM2 inflammasome activation leads to the production of pro-inflammatory cytokines, IL-1β and IL-18 and participates triggering a pyroptosis response needed to counteract excessive cell proliferation. In addition, AIM2 expression and activation is wide regulated since alteration in its activity may derived in pathological consequences. Read More

View Article and Full-Text PDF

Determining treatment response in lupus nephritis.

Authors:
Susan J Allison

Nat Rev Nephrol 2022 Jul 25. Epub 2022 Jul 25.

Nature Reviews Nephrology, .

View Article and Full-Text PDF

Mean platelet volume to lymphocyte ratio and platelet distribution width to lymphocyte ratio in Iraqi patients diagnosed with systemic lupus erythematosus.

Reumatologia 2022 13;60(3):173-182. Epub 2022 Jul 13.

Rheumatology Unit, Department of Internal Medicine, Al Nu'man Teaching Hospital, Baghdad, Iraq.

Introduction: The mean platelet volume to lymphocyte ratio (MPVLR) and platelet distribution width to lymphocyte ratio (PDWLR) have the potential to serve as markers of inflammation which may indicate disease activity. The mean platelet volume to lymphocyte ratio and PDWLR were assessed in patients with systemic lupus erythematosus (SLE) in this study.

Material And Methods: Sixty-two patients with systemic lupus erythematosus and 79 controls who were age and gender matched were included. Read More

View Article and Full-Text PDF

Targeting Multiple End Organs in Lupus and Other Systemic Rheumatic Diseases by Inhibiting Bruton's Tyrosine Kinase.

Front Immunol 2022 8;13:893899. Epub 2022 Jul 8.

The Department of Biomedical Engineering, University of Houston, Houston, TX, United States.

Bruton tyrosine kinase (Btk) plays a vital role in activating and differentiating B-cells and regulating signaling in myeloid cells. Indeed, the potential use of Btk inhibitors in preventing lupus has been reported. Here, we extend these observations to 4 additional models of end-organ inflammation: (a) BWF1 lupus nephritis mice, (b) anti-GBM nephritis, (c) bleomycin-induced systemic sclerosis like skin disease, and (d) bleomycin-induced lung disease. Read More

View Article and Full-Text PDF